Abstract
In the past, high-molecular weight, highly substituted hydroxyethyl starch (HES) 450/0.7, which is mostly used in the United States, has been implicated in bleeding complications, some of them lethal. In Europe, medium-molecular weight HES with a low degree of substitution (0.5) has been preferred. The present study investigated, whether a long-term, high-dose volume therapy with a newly developed 6% HES 130/0.4 (Voluven®) is safe in patients suffering from acute ischemic stroke. In particular, the effects on hemostaseology were examined.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have